Advances in the Clinical Management of Inhibitors in Hemophilia A and B

Inhibitors to factor (F) VIII or FIX are the most serious and challenging complication of hemophilia treatment, increasing morbidity and mortality because bleeds no longer respond to standard clotting factor replacement therapy. For patients with high-titer inhibitors, immune tolerance induction achieved through regular factor exposure is the only proven therapy capable of Inhibitor eradication and is almost always indicated for inhibitors of recent onset. Bypassing therapy is used to treat and prevent bleeding, but neither of the 2 currently available bypassing agents has the predictable hemostatic efficacy of factor replacement in hemophilia patients without inhibitors.
Source: Seminars in Hematology - Category: Hematology Authors: Source Type: research